Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis
Launched by BIOIBERICA · Apr 28, 2008
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary knee OA according to ACR criteria;
- • OA of radiological stages 1 to 3 according to Kellgren-Lawrence;
- • VAS of pain ≥30;
- • PASI ≥ 5.
- Exclusion Criteria:
- • Known allergy to chondroitin sulphate;
- • Other bone and articular diseases such as chondrocalcinosis, Paget's disease, rheumatoid arthritis, psoriatic arthritis, acromegaly, hemochromatosis, Wilson's disease;
- • Patients with skin conditions that could interfere in the clinical trial evaluation
About Bioiberica
Bioiberica is a global biotechnology company dedicated to improving health and wellness through the development of innovative solutions derived from natural sources. With a strong focus on research and development, Bioiberica specializes in the production of high-quality biomolecules, including those used in the pharmaceutical, nutraceutical, and veterinary sectors. The company is committed to advancing scientific knowledge and clinical research, aiming to deliver effective therapeutic options that enhance the quality of life for patients and animals alike. Through its rigorous clinical trials and collaborations with leading institutions, Bioiberica strives to set new standards in healthcare, fostering a culture of sustainability and ethical responsibility.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Barcelona, , Spain
Patients applied
Trial Officials
Pere Benito, MD
Principal Investigator
Hospital del Mar
Montserrat Pérez, MD
Principal Investigator
Instituto Poal de Reumatología
Ingrid Möller, MD
Principal Investigator
Instituto Poal de Reumatología
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials